Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes.

Olivia M Dong Kevin A FriedeCatherine Chanfreau-CoffinierDeepak Voora

Published in: European heart journal. Quality of care & clinical outcomes (2022)

In Veterans post-ACS/PCI, CYP2C19-guided P2Y12 inhibitor selection can improve cardiovascular outcomes and lower costs for the VHA within 12 months of implementation.

Keyphrases

acute coronary syndrome
percutaneous coronary intervention
antiplatelet therapy
st segment elevation myocardial infarction
st elevation myocardial infarction
acute myocardial infarction
coronary artery bypass grafting
coronary artery disease
primary care
healthcare
coronary artery bypass
heart failure